Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiency

Clinical and Vaccine Immunology

Volumn 17, Issue 4, 2010, Pages 524-528

  Rezaei, Nima ^a,b,c   Siadat, Seyed Davar ^d   Aghamohammadi, Asghar ^a,b   Moin, Mostafa ^e   Pourpak, Zahra ^d   Norouzian, Dariush ^d   Mobarakeh, Jalal Izadi ^d   Aghasadeghi, Mohammad Reza ^a   Nejati, Mehdi ^d   Read, Robert C ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MENINGOCOCCUS VACCINE; SERUM BACTERICIDAL ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BRONCHIECTASIS; CHILD; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SCHOOL CHILD; SPLENOMEGALY; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP C; TIME FACTORS; YOUNG ADULT;

EID: 77950630593     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00389-09     Document Type: Article

References (37)

1. Aghamohammadi, A., A. Farhoudi, M. Moin, N. Rezaei, A. Kouhi, Z. Pour-pak, N. Yaseri, M. Movahedi, M. Gharagozlou, F. Zandieh, F. Yazadni, S. Arshi, I. Mohammadzadeh, B. M. Ghazi, M. Mahmoudi, S. Tahaei, and A. Isaeian. 2005. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin. Diagn. Lab. Immunol. 12: 825-832.
2. Aghamohammadi, A., V. Lougaris, A. Plebani, T. Miyawaki, A. Durandy, and L. Hammarström. 2008. Predominantly antibody deficiencies, p. 97-130. In N. Rezaei, A. Aghamohammadi, and L. D. Notarangelo (ed.), Primary immunodeficiency diseases: definition, diagnosis and management, vol.1. Springer-Verlag, Berlin, Germany.
3. Aghamohammadi, A., N. Parvaneh, and N. Rezaei. 2009. Common variable immunodeficiency: a heterogeneous group needs further subclassification. Expert Rev. Clin. Immunol. 5:629-631.
4. Aghamohammadi, A., N. Parvaneh, F. Tirgari, F. Mahjoob, M. Movahedi, M. Gharagozlou, M. Mansouri, A. Kouhi, N. Rezaei, and D. Webster. 2006. Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency. Leuk. Lymphoma 47:343-346.
5. Al-Herz, W., and S. J. McGeady. 2003. Antibody response in common variable immunodeficiency. Ann. Allergy Asthma Immunol. 90:244-247.
6. Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780-786.
7. Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23:2222-2227.
8. Borrow, R., P. Richmond, E. B. Kaczmarski, A. Iverson, S. L. Martin, J. Findlow, M. Acuna, E. Longworth, R. O'Connor, J. Paul, and E. Miller. 2000. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococ-cal A/C polysaccharide vaccine. FEMS Immunol. Med. Microbiol. 28:79-85.
9. Carsetti, R., M. M. Rosado, S. Donnanno, V. Guazzi, A. Soresina, A. Meini, A. Plebani, F. Aiuti, and I. Quinti. 2005. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J. Allergy Clin. Immunol. 115:412-417.
10. Casali, P., and E. W. Schettino. 1996. Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210:167-179.
11. Chapel, H., M. Lucas, M. Lee, J. Bjorkander, D. Webster, B. Grimbacher, C. Fieschi, V. Thon, M. R. Abedi, and L. Hammarstrom. 2008. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112:277-286.
12. Conley, M. E., C. L. Park, and S. D. Douglas. 1986. Childhood common variable immunodeficiency with autoimmune disease. J. Pediatr. 108:915-922.
13. Costantino, P., S. Viti, A. Podda, M. A. Velmonte, L. Nencioni, and R. Rappuoli. 1992. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10:691-698.
14. Cunningham-Rundles, C., and C. Bodian. 1999. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 92:34-48.
15. Cunningham-Rundles, C., and A. K. Knight. 2007. Common variable immune deficiency: reviews, continued puzzles, and a new registry. Immunol. Res. 38:78-86.
16. Geha, R. S., L. Notarangelo, J. L. Casanova, H. Chapel, A. Fischer, L. Hammarstrom, S. Nonoyama, H. Ochs, J. Puck, C. Roifman, R. Seger, and J. Wedgwood. 2007. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J. Allergy Clin. Immunol. 120:776-794.
17. Girard, M. P., M. P. Preziosi, M. T. Aguado, and M. P. Kieny. 2006. A review of vaccine research and development: meningococcal disease. Vaccine 24: 4692-4700.
18. Goldacker, S., R. Draeger, K. Warnatz, D. Huzly, U. Salzer, J. Thiel, et al. 2007. Active vaccination in patients with common variable immunodeficiency (CVID). Clin. Immunol. 124:294-303.
19. Hayakawa, K., and R. R. Hardy. 2000. Development and function of B-1 cells. Curr. Opin. Immunol. 12:346-353.
20. Kimmel, S. R. 2005. Prevention of meningococcal disease. Am. Fam. Physician 72:2049-2056.
21. Ko, J., L. Radigan, and C. Cunningham-Rundles. 2005. Immune competence and switched memory B cells in common variable immunodeficiency. Clin. Immunol. 116:37-41.
22. Kruetzmann, S., M. M. Rosado, H. Weber, U. Germing, O. Tournilhac, H. H. Peter, R. Berner, A. Peters, T. Boehm, A. Plebani, I. Quinti, and R. Carsetti. 2003. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197:939-945.
23. Maslanka, S. E., L. L. Gheesling, D. E. Libutti, K. B. Donaldson, H. S. Harakeh, J. K. Dykes, F. F. Arhin, S. J. Devi, C. E. Frasch, J. C. Huang, P. Kriz-Kuzemenska, R. D. Lemmon, M. Lorange, C. C. Peeters, S. Quataert, J. Y. Tai, and G. M. Carlone. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 4:156-167.
24. Mellemkjaer, L., L. Hammarstrom, V. Andersen, J. Yuen, C. Heilmann, T. Barington, J. Bjorkander, and J. H. Olsen. 2002. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin. Exp. Immunol. 130:495-500.
25. Notarangelo, L., J. L. Casanova, M. E. Conley, H. Chapel, A. Fischer, J. Puck, C. Roifman, R. Seger, and R. S. Geha. 2006. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee meeting in Budapest, 2005. J. Allergy Clin. Immunol. 117:883-896.
26. Nourizadeh, M., A. Aghamohammadi, S. M. Moazzeni, M. Mahdavi, N. Rezaei, and J. Hadjati. 2007. High production of IL-18 by dendritic cells induced by sera from patients with primary antibody deficiency. Iran J. Allergy Asthma Immunol. 6:59-65.
27. Piqueras, B., C. Lavenu-Bombled, L. Galicier, F. Bergeron-van der Cruys-sen, L. Mouthon, S. Chevret, P. Debre, C. Schmitt, and E. Oksenhendler. 2003. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J. Clin. Immunol. 23:385-400.
28. Ramyar, A., A. Aghamohammadi, K. Moazzami, N. Rezaei, M. Yeganeh, T. Cheraghi, N. Pouladi, G. Heydari, K. Abolhassari, A. A. Amirzargar, N. Parvaneh, and M. Moin. 2008. Presence of idiopathic thrombocytopenia purpura and autoimmune hemolytic anemia in the patients with common variable immunodeficiency. Iran J. Allergy Asthma Immunol. 7:169-175.
29. Rezaei, N., A. Aghamohammadi, G. A. Kardar, M. Nourizadeh, and Z. Pourpak. 2008. T-helper 1 and 2 cytokines assay in patients with common variable immunodeficiency. J. Investig. Allergol. Clin. Immunol. 18:449-453.
30. Rezaei, N., A. Aghamohammadi, M. Moin, Z. Pourpak, M. Movahedi, M. Gharagozlou, L. Atarod, B. M. Ghazi, A. Isaeian, M. Mahmoudi, K. Abolmaali, D. Mansouri, S. Arshi, N. J. Tarash, R. Sherkat, H. Akbari, R. Amin, A. Alborzi, S. Kashef, R. Farid, I. Mohammadzadeh, M. S. Shabe-stari, M. Nabavi, and A. Farhoudi. 2006. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian primary immunodeficiency registry. J. Clin. Immunol. 26: 519-532.
31. Rezaei, N., A. Aghamohammadi, and R. C. Read. 2008. Response to poly-saccharide vaccination amongst pediatric patients with common variable immunodeficiency correlates with clinical disease. Iran J. Allergy Asthma Immunol. 7:237-240.
32. Rezaei, N., A. Aghamohammadi, S. D. Siadat, M. Moin, Z. Pourpak, M. Nejati, H. Ahmadi, S. Kamali, D. Norouzian, B. Tabaraei, and R. C. Read. 2008. Serum bactericidal antibody responses to meningococcal polysaccha-ride vaccination as a basis for clinical classification of common variable immunodeficiency. Clin. Vaccine Immunol. 15:607-611.
33. Rezaei, N., A. Aghamohammadi, S. D. Siadat, M. Nejati, H. Ahmadi, M. Moin, Z. Pourpak, S. Kamali, D. Norouzian, B. Tabaraei, and R. C. Read. 2007. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies. Vaccine 25:5308-5314.
34. Rezaei, N., M. Haji-Molla-Hoseini, A. Aghamohammadi, A. A. Pourfathol-lah, M. Moghtadaie, and Z. Pourpak. 2008. Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. J. Clin. Immunol. 28:78-84.
35. Vodjgani, M., A. Aghamohammadi, M. Samadi, M. Moin, J. Hadjati, M. Mirahmadian, N. Parvaneh, A. Salavati, S. Abdollahzade, N. Rezaei, and A. Srrafnejad. 2007. Analysis of class-switched memory B cells in patients with common variable immunodeficiency and its clinical implications. J. Investig. Allergol. Clin. Immunol. 17:321-328.
36. Wehr, C., T. Kivioja, C. Schmitt, B. Ferry, T. Witte, E. Eren, M. Vlkova, M. Hernandez, D. Detkova, P. R. Bos, G. Poerksen, H. von Bernuth, U. Bau-mann, S. Goldacker, S. Gutenberger, M. Schlesier, F. Bergeron-van der Cruyssen, M. Le Garff, P. Debre, R. Jacobs, J. Jones, E. Bateman, J. Litz-man, P. M. van Hagen, A. Plebani, R. E. Schmidt, V. Thon, I. Quinti, T. Espanol, A. D. Webster, H. Chapel, M. Vihinen, E. Oksenhendler, H. H. Peter, and K. Warnatz. 2008. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 111:77-85.
37. Zimmerman, R. K. 2005. Time of hope for the eventual elimination of meningococcal strains A, C, Y, and W-135 in the United States. Am. Fam. Physician 72:1978-1980.